Home/Pipeline/MP0533

MP0533

Acute Myeloid Leukemia (AML)

Phase 1/2Active

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1/2

Status

Active

Company

Molecular Partners

About Molecular Partners

Molecular Partners AG is a pioneer in the development of DARPin (Designed Ankyrin Repeat Protein) therapeutics, an entirely new class of custom-built protein drugs designed to overcome limitations of conventional biologics. The company leverages its proprietary platform to create multi-specific, logic-gated, and radio-conjugated drug candidates, primarily targeting cancers with high unmet need. Its strategy combines in-house R&D expertise with strategic partnerships to advance a diverse pipeline, including its lead programs MP0533 for AML and MP0712 for solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
NTLA-5001	Intellia Therapeutics	Phase 1/2	Active
Galinpepimut-S (GPS)	SELLAS Life Sciences	Phase 2/3	Active
SLS009 (GFH009)	SELLAS Life Sciences	Phase 1/2	Active
UCART123	Cellectis	Phase 1	Active
Iadademstat (ORY-1001)	Oryzon Genomics	Phase 2	Active - Combination with azacitidine
SEL24 (MEN1703)	Selvita	Phase 1/2	Active
Selinexor	Karyopharm Therapeutics	Clinical Trials	Investigational
NEX-20 (azacitidine)	Nanexa AB	Phase 1	Active
SENTI-202	Senti Biosciences	Phase 1	Active - Global clinical trial ongoing
motixafortide (BL-8040)	BioLineRx	Phase 2a	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)